Manufactured by Eli Lilly and Company and first approved in September 2014, Trulicity holds two distinct FDA indications: glycemic control in adults with type 2 diabetes, and cardiovascular risk reduction making it the first and only type 2 diabetes medicine approved to reduce the risk of major cardiovascular events in both patients with established heart disease and those with multiple cardiovascular risk factors but no prior cardiac event (primary and secondary prevention)
The compound incorporates three non-standard structural features: an -aminoisobutyric acid (Aib) at the N-terminus bearing no stereocenter, a D-2-naphthylalanine (D-2-Nal) at position 3, and a D-phenylalanine at position 4
USA 116 , 45674574 (2019)
Neuropharmacology 131, 8395
Further analyses will help in faster detection of HAE patients in Bosnia and Herzegovina, especially asymptomatic familial cases
Navigating medication storage, accidental missteps, and travel logistics can feel complex, but with clear information and supportive resources, it becomes a manageable part of your wellness journey
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
